Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)
Diseases of the Cardiovascular System
What is the purpose of this trial?
The purpose of the study is to collect information on patients who have been diagnosed with transthyretin-associated amyloidosis who carry a mutation in the gene that could lead to this disease.
- Ages18 years and older
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Start Date06/03/2014
- End Date06/29/2021
- Last Updated05/06/2020
- Study HIC#1306012239